Durable Goods (Jun F) -9.4% vs 9.3% Prior, Ex-Trans 0.2% vs 0.2%
Goldman Sachs initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) Monday with a Buy rating and a $37.00 price target, citing positive Phase 1 data for the company’s chronic myeloid leukemia (CML) treatment. The biotech company, currently valued at $1.26 billion, has seen its shares surge 7.72% over the past week. According to InvestingPro data, the company maintains a strong financial health score, with more cash than debt on its balance sheet.
The investment bank highlighted ELVN-001’s consistent efficacy data presented at the European Hematology Association meeting, noting a 47% overall cumulative major molecular response (MMR) rate by 24 weeks, with 41% response in tyrosine kinase inhibitor (TKI)-resistant patients.
Goldman Sachs analysts compared these results favorably to Novartis (SIX:NOVN)’ fourth-generation Scemblix, which showed a 37% overall response rate in its Phase 1 study, with just 9% in TKI-resistant patients.
ELVN-001 demonstrated a well-tolerated safety profile with no increased cardiovascular toxicity, and pharmacokinetic data supports potential once-daily dosing without fasting requirements and low drug-drug interactions, according to the research note.
Enliven plans to initiate a Phase 3 trial in 2026, with Goldman Sachs estimating global peak sales of $1.7 billion by 2035 in second-line and beyond CML treatment, positioning the drug competitively against Novartis’ Scemblix, which has been projected as a $3 billion opportunity.
In other recent news, Enliven Therapeutics has announced a public offering expected to generate approximately $200 million in gross proceeds. This offering includes shares of common stock and pre-funded warrants, with Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho (NYSE:MFG) serving as joint book-running managers. Additionally, Enliven reported promising data from its Phase 1 ENABLE trial for ELVN-001, a therapy for chronic myeloid leukemia, showing a 47% cumulative major molecular response rate by 24 weeks. Analysts have taken note of these developments, with Mizuho Securities raising its price target for Enliven to $41, citing the company’s validated science and market potential. BTIG also increased its price target to $45, highlighting the company’s strategic shift to focus on the ELVN-001 therapy and its forthcoming pivotal trial. Enliven plans to seek strategic alternatives for its HER2 TKI program, ELVN-002, discontinuing its development beyond 2025. The company holds $289.6 million in cash and cash equivalents, expected to support operations into late 2027. These recent developments reflect Enliven’s ongoing efforts to advance its oncology programs and secure funding for future initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.